Ikena Oncology Receivables 2021-2025 | IKNA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Ikena Oncology receivables from 2021 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Ikena Oncology receivables from 2021 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$220.6B
Amgen (AMGN)	$158.8B
Gilead Sciences (GILD)	$136.4B
Vertex Pharmaceuticals (VRTX)	$120.4B
Bristol Myers Squibb (BMY)	$95.4B
GSK (GSK)	$78.4B
CSL (CSLLY)	$76.6B
Regeneron Pharmaceuticals (REGN)	$61.3B
Alnylam Pharmaceuticals (ALNY)	$41.1B
Argenex SE (ARGX)	$34.3B
BioNTech SE (BNTX)	$27.1B
Royalty Pharma (RPRX)	$20.2B
Biogen (BIIB)	$19.7B
Insmed (INSM)	$18.6B
Illumina (ILMN)	$15.7B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.7B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$13B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.4B
Roivant Sciences (ROIV)	$7.7B
Repligen (RGEN)	$7.3B